Comparator: Sitagliptin
Drugsitagliptin 10 mg tablet, once daily for 54 weeks
NCT Number: NCT00106704
The purpose of this clinical study is to determine the safety and efficacy of an investigational drug in patients with Type 2 diabetes mellitus.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Phase 3
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
sitagliptin 10 mg tablet, once daily for 54 weeks
Placebo oral tablet once daily for 24 weeks
Pioglitazone 30 mg tablet once daily for 30 weeks
Time frame: Baseline and 24 Weeks
Hemoglobin A1C (A1C) is measured as percent. Thus this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.
Time frame: Baseline and 24 Weeks
The change from baseline is the Week 24 Fasting Plasma Glucose (FPG) minus the Week 0 FPG.
Merck Sharp & Dohme LLC
Industry
A Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of the Addition of MK0431 to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Glimepiride Alone or in Combination With Metformin
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06326047
Diabetes Mellitus, Diabetes Mellitus, Type 2
Chula Vista, California, United States
View Trial DetailsNCT06423729
Body Weight, Diabetes Mellitus
Tanta, Egypt
View Trial DetailsNCT00418522
Diabetes Mellitus, Diabetes Mellitus, Type 2
Phoenix, Arizona, United States
View Trial DetailsNCT04760626
Diabetes Mellitus, Diabetes Mellitus, Type 2
Birmingham, Alabama, United States
View Trial Details